Yet, in another KMT2A-rearranged ALL cell line, acquired revumenib resistance was developed in the absence of MEN1 mutations, suggesting alternative mechanisms of reduced responsiveness to menin inhibition. This evidence concerns the gene MEN1 and acute lymphoblastic leukemia.